» Articles » PMID: 30627128

Oral Administration of Human Polyvalent IgG by Mouthwash As an Adjunctive Treatment of Chronic Oral Candidiasis

Overview
Journal Front Immunol
Date 2019 Jan 11
PMID 30627128
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

is a commensal fungus that can cause disease ranging in severity from moderate to severe mucosal infections to more serious life-threating disseminated infections in severely immunocompromised hosts. Chronic mucocutaneous candidiasis (CMC) occurs in patients with mutations in genes affecting IL-17-mediated immunity, such as , and , or gain of function (GOF) mutations in . New strategies for the treatment of candidiasis are needed because of the increased burden of infections and the emergence of drug-resistant strains. In this study, we investigated an aspect of the role of antibodies in the control of infection. We tested the effects of opsonization with commercial human polyvalent intravenous IgG (IV IgG) on NADPH oxidase activity and killing of the fungi by blood leukocytes from 11 healthy donors and found a significant enhancement in both phenomena that was improved by IV IgG opsonization. Then, we hypothesized that the opsonization of could help its elimination by mucosal phagocytes in human patients with mucocutaneous candidiasis. We tested a novel adjunctive treatment for oral candidiasis in humans based on topical treatment with IV IgG. For this purpose, we choose two pediatric patients with well-characterized primary immunodeficiencies who are susceptible to CMC. Two 8-year-old female patients with an autosomal recessive mutation in the gene (P1, with oral candidiasis) and a GOF mutation in (P2, with severe CMC persistent since the age of 8 months and resistant to pharmacological treatments) were treated with IV IgG administered daily three times a day as a mouthwash over the course of 2 weeks. The treatment with the IV IgG mouthwash reduced mouth infection by 98 and 70% in P1 and P2, respectively, after 13 days, and complete fungal clearance was observed after complementary nystatin and caspofungin treatments, respectively. Therefore, treatment of oral candidiasis with human polyvalent IgG administered as a mouthwash helps eliminate mucosal infection in humans, circumventing drug resistance, and opening its potential use in patients with primary or transient immunodeficiency.

Citing Articles

Chinese Chronic Mucocutaneous Candidiasis: A Case Report Series.

Qian G, Zhang J, Shi L, Li D, Yang B, Chen B Infect Drug Resist. 2024; 17:1869-1877.

PMID: 38745679 PMC: 11092975. DOI: 10.2147/IDR.S456121.


Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance.

Pedraza-Sanchez S, Cruz-Gonzalez A, Palmeros-Rojas O, Galvez-Romero J, Bellanti J, Torres M Front Immunol. 2023; 13:987231.

PMID: 36713426 PMC: 9880058. DOI: 10.3389/fimmu.2022.987231.


Antifungal antibodies present in intravenous immunoglobulin derived from China.

Wang Y, Liu Y, Jiang S, Zhao Y, Cai J, Hao W Braz J Microbiol. 2023; 54(1):81-92.

PMID: 36602749 PMC: 9944592. DOI: 10.1007/s42770-022-00894-z.


Could β-Lactam Antibiotics Block Humoral Immunity?.

Melenotte C, Pontarotti P, Pinault L, Mege J, Devaux C, Raoult D Front Immunol. 2021; 12:680146.

PMID: 34603278 PMC: 8480522. DOI: 10.3389/fimmu.2021.680146.


Primary Immunodeficiencies With Defects in Innate Immunity: Focus on Orofacial Manifestations.

Jung S, Gies V, Korganow A, Guffroy A Front Immunol. 2020; 11:1065.

PMID: 32625202 PMC: 7314950. DOI: 10.3389/fimmu.2020.01065.


References
1.
Srivastava V, Singla R, Dubey A . Emerging Virulence, Drug Resistance and Future Anti-fungal Drugs for Candida Pathogens. Curr Top Med Chem. 2018; 18(9):759-778. DOI: 10.2174/1568026618666180528121707. View

2.
Moragues M, Omaetxebarria M, Elguezabal N, Sevilla M, Conti S, Polonelli L . A monoclonal antibody directed against a Candida albicans cell wall mannoprotein exerts three anti-C. albicans activities. Infect Immun. 2003; 71(9):5273-9. PMC: 187351. DOI: 10.1128/IAI.71.9.5273-5279.2003. View

3.
Lehrer R, Cline M . Interaction of Candida albicans with human leukocytes and serum. J Bacteriol. 1969; 98(3):996-1004. PMC: 315286. DOI: 10.1128/jb.98.3.996-1004.1969. View

4.
Pedraza-Sanchez S, Lezana-Fernandez J, Gonzalez Y, Martinez-Robles L, Ventura-Ayala M, Sadowinski-Pine S . Disseminated Tuberculosis and Chronic Mucocutaneous Candidiasis in a Patient with a Gain-of-Function Mutation in Signal Transduction and Activator of Transcription 1. Front Immunol. 2017; 8:1651. PMC: 5723642. DOI: 10.3389/fimmu.2017.01651. View

5.
Wang X, Sui X, Yan L, Wang Y, Cao Y, Jiang Y . Vaccines in the treatment of invasive candidiasis. Virulence. 2015; 6(4):309-15. PMC: 4601158. DOI: 10.4161/21505594.2014.983015. View